20-F: Alpha Tau Medical Reports Annual Results for 2024, Highlights Clinical Progress

Alpha Tau Medical's 2024 annual report details the company's financial status and ongoing clinical trials for its Alpha DaRT technology.

Summary

• Alpha Tau Medical Ltd. released its annual report for the fiscal year ended December 31, 2024.
• The company is a clinical-stage oncology therapeutics company focused on localized radiation therapy for solid tumors using its Alpha DaRT technology.
• Alpha Tau Medical has not generated any revenue to date and incurred a net loss of $31.75 million in 2024, compared to a net loss of $29.16 million in 2023.
• As of December 31, 2024, the company had cash and cash equivalents of $62.86 million, which is expected to fund operations into 2026.
• The company is pursuing marketing authorization for its Alpha DaRT technology, with a focus on the United States.
• Clinical trials are ongoing for various cancer types, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers.
• The company submitted an application for pre-market approval in Japan for recurrent head and neck cancer.
• Alpha Tau is exploring strategic partnerships to complement its development and commercialization efforts.
• The company's patent portfolio includes 151 issued patents and 217 pending patent applications as of December 31, 2024.
• Alpha Tau is subject to extensive government regulation and oversight, both in the United States and abroad.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is making progress in its clinical trials and has a promising technology, it is still in the development stage and has not generated any revenue. The company also faces significant risks and uncertainties.

Positives

• The FDA granted Breakthrough Device Designation for Alpha DaRT in skin and oral cavity SCC and recurrent Glioblastoma Multiforme.
• Interim data from pancreatic cancer trials showed an 18% objective response rate and 91% disease control rate.
• Interim data from a pembrolizumab combination trial in HNSCC showed a 75% systemic objective response rate.
• The company is exploring strategic partnerships to complement its development and commercialization efforts.

Negatives

• Alpha Tau Medical has not generated any revenue to date.
• The company's net loss increased to $31.75 million in 2024 from $29.16 million in 2023.

Risks

• The company may need substantial additional funding, and if unable to raise capital, could delay or terminate development programs.
• The commercial success of Alpha DaRT depends on public perception of radiation therapies and market acceptance by physicians and patients.
• The company's Alpha DaRT technology and operations are subject to extensive government regulation and oversight.
• The company may not receive necessary marketing authorizations or certifications for its Alpha DaRT technology.
• The company may be unable to obtain a sufficient supply of radioisotopes to support clinical development or at commercial scale.
• Conditions in Israel could materially and adversely affect the company's business.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future as it continues clinical trials, seeks regulatory approvals, and scales manufacturing processes.

Industry Context

The announcement reflects the ongoing innovation and competition in the oncology therapeutics space, particularly in radiation therapy and radiopharmaceuticals. The company's focus on alpha particles represents a novel approach compared to traditional beta and gamma radiation therapies.

Comparison to Industry Standards

• The company's approach to alpha radiation therapy is comparable to Bayer's Xofigo, but Alpha Tau is focused on localized treatment rather than systemic delivery.
• The company's combination trials with pembrolizumab are similar to Merck's KEYNOTE-048 study in HNSCC.
• The company's development of manufacturing facilities is similar to other medical device companies scaling up production for commercial launch.

Related Party Transactions

• The company has entered into employment or consulting agreements with each of its executive officers, and in certain situations, at arms-length terms, with family members of its executive officers or directors.
• Since our founding, we have granted options to purchase ordinary shares to our executive officers and directors.
• Additionally, since August 2021, we have granted restricted share units to our executive officers and directors.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will impact shareholder value.
• Employees: The company's ability to secure funding and achieve its goals will impact employee job security and compensation.
• Patients: The company's Alpha DaRT technology has the potential to improve treatment outcomes for cancer patients.
• Healthcare providers: The company's Alpha DaRT technology could provide a new treatment option for solid tumors.

Next Steps

• Complete the ongoing U.S. clinical trial evaluating the efficacy and safety of Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma tumors.
• Advance the global development pipeline by conducting feasibility studies in other tumors of high unmet need or metastatic diseases, and accelerate the initiation of similar U.S. trials.
• Continue to evaluate the potential systemic immune response generated by the Alpha DaRT, particularly in combination with immunotherapies.
• Expand independent manufacturing capabilities across strategic geographical regions.
• Pursue marketing authorization and, if authorized, third-party payor coverage in multiple geographies, with a focus on the United States.

Key Dates